An existing body of literature shows that marital status and related social support are connected with disease outcomes.
Researchers report that the same driving force that makes Zika so detrimental to unborn babies gives it promise as a cancer treatment.
New data support PFS as a surrogate endpoint for OS in future trials evaluating chemoimmunotherapy in DLBCL.
In the DBL3001 trial, the combination of ibrutinib and R-CHOP was not superior to treatment with R-CHOP alone.
Are you up-to-date on treatment regimens for previously treated multiple myeloma? Take our latest quiz to sharpen your knowledge.
A laboratory study found that combining anti-HER2 TKIs with trastuzumab and pertuzumab can result in enhanced anticancer activity in HER2+ breast cancer cell lines.
Intravenous Iobenguane I 131 has been approved to treat unresectable, locally advanced, or metastatic pheochromocytoma.
Internal mammary chain radiation therapy for breast cancer is associated with increased cardiac toxicity, in particular when paired with anthracyclines.
Many breast cancer patients report that clinicians do not engage adequately regarding management of financial toxicity associated with their diagnosis, according to a new survey.
The lesion in the right side of the patient’s back does not appear to be in soft tissue without involvement of epidermis. Surgical resection is performed. What is your diagnosis?
The inverse association between circulating DBP and risk of RCC support emerging evidence for an etiologic role of DBP in cancer.
A nested case-control study found that the association between obesity and RCC varies depending on subtype.
Chemoimmunotherapy followed by lenalidomide consolidation is tolerated and extends PFS and OS in CLL patients.
The addition of bevacizumab to adjuvant chemotherapy regimens does not improve survival in women with high-risk breast cancer.
Smoking cessation and relapse prevention expert Alan Blum, MD, discusses how oncologists and other clinicians can and should play a larger role in tobacco control.